The Progressive Familial Intrahepatic Cholestasis (PFIC) market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Progressive Familial Intrahepatic Cholestasis: An Overview
According to the National Institute of Health (NIH), (PFIC) is a disorder that causes progressive liver disease, which typically leads to liver failure in which liver cells are unable to secrete a digestive fluid called bile. The buildup of bile in liver cells causes liver disease in affected individuals. The average age at onset is three months, although some patients do not develop jaundice until later, even as late as adolescence. PFIC can progress rapidly and cause cirrhosis during infancy or may progress relatively slowly with minimal scarring into adolescence. Few patients survive into the third decade of life without treatment.
There are mainly three types of PFIC that occur due to mutations in the genes, such as ATP8B1, ABCB11, and ABCB4, which result in the development of PFIC1, PFIC2, and PFIC3 respectively.
Progressive Familial Intrahepatic Cholestasis Market Key Facts
-
The United Kingdom-based study titled “Systematic review of progressive familial intrahepatic cholestasis” conducted by Baker et al. found that the incidence of intrahepatic cholestasis was 1 per 18,000 live births. The researchers also referred to a study in which infants and children (2–18 years) with cholestasis were 12–13% with genetically diagnosed PFIC.
-
According to a Davit-Spraul et al., titled as “Progressive familial intrahepatic cholestasis”, the estimated incidence varies between 1 per 50,000 and 1 per 100,000 births in PFIC patients. It was also found that PFIC1 and PFIC2 represented two out of three cases of total PFIC, whereas PFIC3 was one case per three cases.
Progressive Familial Intrahepatic Cholestasis (PFIC) Market
The Progressive Familial Intrahepatic Cholestasis (PFIC) market size is expected to increase during the forecast period owing to the rise in prevalent cases in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Progressive Familial Intrahepatic Cholestasis market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Progressive Familial Intrahepatic Cholestasis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Progressive Familial Intrahepatic Cholestasis (PFIC) Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
PFIC Epidemiology Segmentation –
-
Prevalent Population of PFIC
-
Type-specific Prevalent Population of PFIC
Progressive Familial Intrahepatic Cholestasis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Familial Intrahepatic Cholestasis market or expected to get launched during the study period. The analysis covers Progressive Familial Intrahepatic Cholestasis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Progressive Familial Intrahepatic Cholestasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market
Progressive Familial Intrahepatic Cholestasis (PFIC) Therapeutics Analysis
Currently, Progressive Familial Intrahepatic Cholestasis (PFIC) market does not hold any approved interventions but changes in the diet, medicines, and surgical treatments can reduce the effects and complications of the condition. The treatment, which is generally symptomatic involves observation by the expert physicians depending on the features and severity of the condition and its effects.
Some of the key companies in the PFIC Market include:
-
Albireo
-
Mirum Pharmaceuticals
-
Vivet Therapeutics
And many others.
PFIC Therapies covered in the report include:
-
Maralixibat
-
A4250 (Odevixibat)
-
VTX-802 and VTX-803
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies –
https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Progressive Familial Intrahepatic Cholestasis Competitive Intelligence Analysis
4. Progressive Familial Intrahepatic Cholestasis Market Overview at a Glance
5. Progressive Familial Intrahepatic Cholestasis Disease Background and Overview
6. Progressive Familial Intrahepatic Cholestasis Patient Journey
7. Progressive Familial Intrahepatic Cholestasis Epidemiology and Patient Population
8. Progressive Familial Intrahepatic Cholestasis Treatment Algorithm, Current Treatment, and Medical Practices
9. Progressive Familial Intrahepatic Cholestasis Unmet Needs
10. Key Endpoints of Progressive Familial Intrahepatic Cholestasis Treatment
11. Progressive Familial Intrahepatic Cholestasis Marketed Products
12. Progressive Familial Intrahepatic Cholestasis Emerging Therapies
13. Progressive Familial Intrahepatic Cholestasis Seven Major Market Analysis
14. Attribute Analysis
15. Progressive Familial Intrahepatic Cholestasis Market Outlook (7 major markets)
16. Progressive Familial Intrahepatic Cholestasis Access and Reimbursement Overview
17. KOL Views on the Progressive Familial Intrahepatic Cholestasis Market.
18. Progressive Familial Intrahepatic Cholestasis Market Drivers
19. Progressive Familial Intrahepatic Cholestasis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report –
https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Latest Reports By DelveInsight
Structural Heart Devices Market
Global Structural Heart Devices Market was valued at USD 8.82 billion in 2020, growing at a CAGR of 11.23% during the forecast period from 2021 to 2026, it is expected to reach USD 16.70 billion by 2026. Some of the key companies in the Structural Heart Devices Market include Medtronic, Boston Scientific Corporation, Braile Biomedica, JOTEC GmbH, Edwards Life Sciences Corporation, Valcare Medical, W. L. Gore & Associates, Abbott, Cardiovascular Systems, XELTIS BV, JenaValve Technology, Biomerics, Lepu Medical Technology (Beijing), Livanova, Comed B.V., TORAY INDUSTRIES, Occlutech International AB, Microport Scientific Corporation and others.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/